Antibodies that bind TNFRSF25
Provided herein are antibodies and antibody fragments that bind to human TNFRSF25. The antibodies may be monoclonal and/or biparatopic antibodies and/or single-chain fragment variable (scFv) antibodies. Methods of treating or preventing diseases or disorders associated with inflammation and/or autoimmunity are provided, comprising administering to a patient in need thereof an effective amount of a human TNFRSF25-binding antibody.
1 . A monoclonal antibody or antibody fragment that binds to tumor necrosis factor receptor super-family 25 (TNFRSF25) comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 134 and a light chain comprising the amino acid sequence of SEQ ID NO: 57.
2 . The monoclonal antibody or antibody fragment of claim 1 , wherein the antibody is a chimeric antibody, a biparatopic antibody, or a bispecific antibody.
3 . The monoclonal antibody or antibody fragment of claim 1 , wherein the antibody is an IgG antibody or a recombinant IgG antibody or antibody fragment.
4 . An isolated nucleic acid encoding the antibody heavy and/or light chain region of the antibody or antibody fragment of claim 1 .
5 . An expression vector comprising the nucleic acid of claim 1 .
6 . A hybridoma or engineered cell comprising a nucleic acid encoding the antibody or antibody fragment of claim 1 .
7 . A hybridoma or engineered cell comprising the nucleic acid of claim 4 .
8 . A method of making the monoclonal antibody or antibody fragment of claim 1 , the method comprising culturing a hybridoma or engineered cell comprising a nucleic acid encoding the antibody or antibody fragment under conditions that allow expression of the antibody or antibody fragment and optionally isolating the antibody or antibody fragment from the culture.
9 . A pharmaceutical formulation comprising one or more antibody or antibody fragment of claim 1 .
10 . A method of treating a patient having a disease or disorder associated with inflammation and/or autoimmunity, the method comprising administering to the patient the pharmaceutical formulation of claim 9 .
11 . The method of claim 10 , wherein the disease or disorder is ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, atherosclerosis, asthma, multiple sclerosis, primary biliary cirrhosis, systemic lupus erythematosus, or ankylosing spondylitis.
12 . The method of claim 10 , wherein the administering preserves epithelial barrier integrity.
13 . The method of claim 10 , wherein the administering blocks TL1A binding to cell-surface TNFRSF25.
14 . The method of claim 10 , wherein the administering blocks TL1A-induced secretion of TNFalpha, IL-6, GM-CSF, and IFNgamma.